Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Verve Therapeutics, Inc. VERV
$17.33
-$0.79 (-4.55%)
На 18:04, 12 мая 2023
-24.99%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1105853694.00000000
-
week52high
43.00
-
week52low
10.70
-
Revenue
1941000
-
P/E TTM
-6
-
Beta
0.00000000
-
EPS
-2.93000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stifel | Buy | Hold | 25 авг 2022 г. |
| BMO Capital | Outperform | Outperform | 18 июл 2022 г. |
| BMO Capital | Outperform | 17 июн 2022 г. | |
| RBC Capital | Outperform | 18 февр 2022 г. | |
| Stifel | Hold | 24 сент 2021 г. | |
| Credit Suisse | Neutral | 06 окт 2022 г. | |
| RBC Capital | Outperform | Outperform | 08 ноя 2022 г. |
| Goldman Sachs | Sell | 15 дек 2022 г. | |
| Cantor Fitzgerald | Neutral | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bellinger Andrew | D | 179994 | 36000 | 14 дек 2022 г. |
| Bellinger Andrew | A | 42629 | 36000 | 14 дек 2022 г. |
| Bellinger Andrew | D | 6629 | 865 | 01 дек 2022 г. |
| Dorval Allison | D | 5625 | 1875 | 29 ноя 2022 г. |
| Dorval Allison | D | 2186 | 554 | 29 ноя 2022 г. |
| Dorval Allison | A | 2740 | 1875 | 29 ноя 2022 г. |
| Yeshwant Krishna | D | 4260047 | 243 | 04 ноя 2022 г. |
| Yeshwant Krishna | D | 4260290 | 650 | 04 ноя 2022 г. |
| Yeshwant Krishna | D | 4260940 | 47690 | 04 ноя 2022 г. |
| Yeshwant Krishna | D | 6108442 | 48583 | 04 ноя 2022 г. |
Новостная лента
7 CRISPR Stocks With the Best Long-Term Potential
InvestorPlace
30 янв 2023 г. в 19:10
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool
15 дек 2022 г. в 11:20
The growth-focused money manager is making moves.
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
Investors Business Daily
05 дек 2022 г. в 09:22
The FDA has a bevy of safety concerns surrounding Verve's gene-editing approach to high cholesterol, leading VERV stock to dive Monday. The post Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns appeared first on Investor's Business Daily.
Verve Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
11 ноя 2022 г. в 06:30
BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in fireside chats during the following upcoming investor conferences:
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
The Motley Fool
07 ноя 2022 г. в 14:03
A trial for the company's lead therapy was put on hold.